HilleVax (HLVX)
(Real Time Quote from BATS)
$1.89 USD
+0.05 (2.72%)
Updated Jul 25, 2024 10:52 AM ET
2-Buy of 5 2
D Value D Growth B Momentum D VGM
HilleVax, Inc. (HLVX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$3.00 | $5.00 | $2.00 | 63.04% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for HilleVax, Inc. comes to $3.00. The forecasts range from a low of $2.00 to a high of $5.00. The average price target represents an increase of 63.04% from the last closing price of $1.84.
Analyst Price Targets (4 )
Broker Rating
HilleVax, Inc. currently has an average brokerage recommendation (ABR) of 3.00 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by five brokerage firms. The current ABR compares to an ABR of 1.00 a month ago based on five recommendations.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/HLVX.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 5 | 5 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.00 | 3.00 | 1.00 | 1.00 | 1.00 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/9/2024 | SVB Securities | David Risinger | Strong Buy | Hold |
7/9/2024 | Not Identified | Not Identified | Hold | Hold |
7/9/2024 | H.C. Wainwright & Co. | Matthew Caufield | Strong Buy | Hold |
7/8/2024 | Guggenheim Securities | Seamus Fernandez | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.00 |
ABR (Last week) | 3.00 |
# of Recs in ABR | 5 |
Average Target Price | $3.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -0.73 |